Melanoma Clinical Trials in Massachusetts

Showing 21-40 of 120 trials

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

NCT04305145

The goal of this clinical trial is to compare the safety and effectiveness of infliximab compared to steroids for the treatment of immune checkpoint inhibitor-induced colitis (ICI colitis) in patients with stage III/IV skin cancer. The main questions this study aims to answer are: * How many patients treated with infliximab experience steroid-free disease resolution after 7 weeks? * How many patients treated with steroids experience steroid-free disease resolution after 7 weeks?

Melanoma Stage IIIMelanoma Stage IVSkin Cancer Stage III+4 more

Massachusetts General Hospital42 participantsStarted Aug 2020

Boston, Massachusetts, United States • Boston, Massachusetts, United States

COMPLETEDPHASE1/PHASE226 miles

The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma

NCT00626860

This study aims to determine if the vacccine can be used safely in patients with advanced melanoma (cancer of the pigment cells) and whether the cells in this vaccine are capabale of producing immune responses against your own cancer.

Metastatic Melanoma

Beth Israel Deaconess Medical Center20 participantsStarted Jul 2000

Boston, Massachusetts, United States

TERMINATEDPHASE326 miles

A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma

NCT05002569

The purpose of this study is to assess nivolumab plus relatlimab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma.

Melanoma

Bristol-Myers Squibb1,093 participantsStarted Oct 2021

Birmingham, Alabama, United States • Springdale, Arkansas, United States • Los Angeles, California, United States +181 more locations

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma

A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma

Melanoma Trials in Other Cities

Patient Satisfaction With Appearance, Scar Outcome and Quality of Life After Skin Cancer Surgery

Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)

Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy

Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study

Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)

A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

A Study of SEA-CD40 Given With Other Drugs in Cancers

Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

Other Conditions in Massachusetts